Detralex tab. p / o captivity. 500 mg # 60

Release form, composition and packaging

Orange-pink film-coated tablets, oval

at the fracture - from pale yellow to yellow, heterogeneous structure.

1 tab.

purified micronized flavonoid fraction

500 mg,

incl.

diosmin

450 mg (90%)

flavonoids in terms of hesperidin

50 mg (10%)

gelatin - 31 mg, magnesium stearate - 4 mg, microcrystalline cellulose - 62 mg, sodium carboxymethyl starch - 27 mg, talc - 6 mg, purified water - 20 mg.

The composition of the film shell: macrogol 6000 - 0.710 mg, sodium lauryl sulfate - 0.033 mg, a premix for a film shell of orange-pink color (glycerol - 0.415 mg, magnesium stearate - 0.415 mg, hypromellose - 6.886 mg, iron dye yellow oxide - 0.161 mg, dye iron oxide red - 0.054 mg, titanium dioxide - 1.326 mg).

14 pcs.

- blisters (2) - cardboard packs.

14 pcs.

- blisters (4) - cardboard packs.

15 pcs.

- blisters (2) - cardboard packs.

15 pcs.

- blisters (4) - packs of cardboard. Pharmacological action: Detralex possesses venotonic and angioprotective properties.

The drug reduces the distensibility of veins and venous stasis, reduces capillary permeability and increases their resistance.

The results of clinical studies confirm the pharmacological activity of the drug in relation to the parameters of venous hemodynamics.

The statistically significant dose-dependent effect of Detralex was demonstrated for the following venous plethysmographic parameters: venous capacity, venous extensibility, and venous emptying time.

The optimal dose-response ratio is observed with 2 tablets.

Detralex increases venous tone: with the help of venous occlusive plethysmography, a decrease in the time of venous emptying has been shown.

In patients with signs of severe microcirculation disorders, after therapy with Detralex, an increase in capillary resistance, assessed by the method of angiostereometry, is noted (statistically significant, compared with placebo).

The therapeutic efficacy of Detralex has been proven in the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids.

The drug undergoes active metabolism, as evidenced by the presence of phenolic acids in the urine.

Withdrawal

It is excreted from the body mainly with feces.

With urine, on average, about 14% of the taken amount of the drug is excreted.

T1 / 2 is 11 hours Indications for use Detralex is indicated for the treatment of symptoms of chronic venous diseases (elimination and relief of symptoms).

Therapy for symptoms of venous lymphatic insufficiency:

pain

cramps of the lower extremities

feeling of heaviness and fullness in the legs

tiredness" of the legs.

Therapy of manifestations of venous-lymphatic insufficiency:

swelling of the lower extremities

trophic changes in the skin and subcutaneous tissue

venous trophic ulcers.

Symptomatic therapy of acute and chronic hemorrhoids. Contraindications for use Hypersensitivity to the active ingredients or excipients of the drug.

It is not recommended to take the drug for lactating women. Dosing regimen The drug is prescribed inside.

The recommended dose for venous lymphatic insufficiency is 2 tablets / day (for 1 or 2 doses): in the morning, afternoon and / or evening, during meals.

The duration of the course of treatment can be several months (up to 12 months).

In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated.

The recommended dose for acute hemorrhoids is 6 tablets / day: 3 tablets each.

in the morning and 3 tab.

in the evening for 4 days, then - 4 tab. / day: 2 tab.

in the morning and by

Name ENG

DETRALEX

Clinical and pharmacological group

Venotonic and venoprotective drug

ATX code

Diosmin in combination with other drugs

Dosage

500mg

Structure

1 tablet contains: Active ingredients: purified micronized flavonoid fraction 500 mg (including diosmin (90%) 450 mg, flavonoids, expressed as hesperidin (10%) 50 mg).

Excipients: gelatin, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, talc, glycerol, macrogol 6000, hydroxypropyl methylcellulose, iron oxide yellow (E172), iron oxide red (E172), titanium dioxide (E171), sodium lauryl sulfate.

Indications

DetralexR is indicated for the treatment of symptoms of chronic venous diseases (elimination and relief of symptoms).

Therapy of symptoms of venous-lymphatic insufficiency: -pain

-convulsions of the lower extremities

- a feeling of heaviness and fullness in the legs

- "tiredness" of the legs.

Therapy of manifestations of venous lymphatic insufficiency: edema of the lower extremities

trophic changes in the skin and subcutaneous tissue

venous trophic ulcers.

Symptomatic therapy of acute and chronic hemorrhoids

Contraindications

Hypersensitivity to active ingredients or to excipients that make up the drug.

It is not recommended to take the drug for lactating women.

Storage conditions and periods

At a temperature not higher than 30 degrees.

Expiration date: 4 years

INN / Active ingredient

Hesperidin, Diosmin

Specifications

Category

Diseases of the veins

Scope of the drug

Heart, vessels, blood

Release form

Tablet

Manufacturer country

Russia

Package quantity, pcs

60

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

Servier

The amount of the dosage form in the primary package

15 pcs.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Venotonic and venoprotective agent

Anatomical and therapeutic characteristics

C05CA53 Diosmin, in combination with other drugs

Dosage form

Film-coated tablets

Expiration date in days

1460

Package weight, g

fifty

Mode of application

:

The drug is taken orally.

< br> The recommended dose is 2 tablets per day, 1 tablet - in the middle of the day and 1 tablet - in the evening during meals.

< br> During the period of exacerbation of hemorrhoids - 6 tablets per day for 4 days, then 4 tablets per day for the next 3 days.

Dosage (volume) of the substance in the preparation

:

Purified micronized flavonoid fraction 500 mg (of which diosmin (90%) 450 mg, flavonoids, expressed as hesperidin (10%) 50 mg)

Information on technical characteristics, delivery set, country of manufacture "